Lepu Biopharma (2157.HK) announces 2025 interim results Aug 21, 2025 14:38 HKT/SGT - ADC pipeline with multiple products entering key clinical stages- Revenue increased by 350% year-on-year
Lepu Biopharma: Puyouheng (pucotenlimab injection) obtains approval for marketing with a new indication, Breakthrough therapy designation granted by the CDE to MRG003 for the treatment of R/M NPC Sep 29, 2022 15:40 HKT/SGT
Lepu Biopharma Co., Ltd. Successfully Listed on the Main Board of HKEX Feb 23, 2022 18:11 HKT/SGT First Day Closed at HK$7.14, HK$0.01 Higher Than the Offer PriceRepresenting an Increase of Approximately 0.14%
乐普生物宣布于香港交易所主板上市计划 Feb 10, 2022 09:52 HKT/SGT 每股H股作价6.87港元至7.38港元 集资额最多936.3百万港元拥有从药物发现、临床开发、CMC到GMP合规生产的一体化的端到端平台已构建具备临床疗效与商业化协同的产品管线
樂普生物宣佈於香港交易所主板上市計劃 Feb 10, 2022 09:51 HKT/SGT 每股H股作價6.87港元至7.38港元 集資額最多936.3百萬港元擁有從藥物發現、臨床開發、CMC到GMP合規生產的一體化的端到端平台已構建具備臨床療效與商業化協同的產品管線